Robert W. Baker

6.7k total citations · 1 hit paper
90 papers, 4.6k citations indexed

About

Robert W. Baker is a scholar working on Psychiatry and Mental health, Cellular and Molecular Neuroscience and Clinical Psychology. According to data from OpenAlex, Robert W. Baker has authored 90 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 52 papers in Psychiatry and Mental health, 11 papers in Cellular and Molecular Neuroscience and 11 papers in Clinical Psychology. Recurrent topics in Robert W. Baker's work include Schizophrenia research and treatment (37 papers), Bipolar Disorder and Treatment (28 papers) and Electroconvulsive Therapy Studies (26 papers). Robert W. Baker is often cited by papers focused on Schizophrenia research and treatment (37 papers), Bipolar Disorder and Treatment (28 papers) and Electroconvulsive Therapy Studies (26 papers). Robert W. Baker collaborates with scholars based in United States, United Kingdom and Canada. Robert W. Baker's co-authors include Mauricio Tohen, Richard C. Risser, Craig R. Rush, Joseph R. Calabrese, Charles L. Bowden, Alan Breier, Carlos A. Zarate, Bohdan Siryk, Angela R. Evans and Trisha Suppes and has published in prestigious journals such as Gastroenterology, American Journal of Psychiatry and Scientific Reports.

In The Last Decade

Robert W. Baker

88 papers receiving 4.2k citations

Hit Papers

Efficacy of Olanzapine and Olanzapine-Fluoxetine Combinat... 2003 2026 2010 2018 2003 200 400 600

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert W. Baker United States 35 3.4k 740 609 440 396 90 4.6k
Paul Grof Canada 43 5.0k 1.5× 498 0.7× 1.5k 2.4× 361 0.8× 407 1.0× 198 6.5k
Rasmus Wentzer Licht Denmark 34 3.3k 1.0× 608 0.8× 802 1.3× 136 0.3× 515 1.3× 114 4.2k
Joseph F. Goldberg United States 46 5.6k 1.6× 1.0k 1.4× 2.0k 3.3× 230 0.5× 380 1.0× 180 6.9k
Michael J. Ostacher United States 42 5.1k 1.5× 981 1.3× 2.0k 3.3× 310 0.7× 284 0.7× 119 6.6k
David G. Daniel United States 28 2.7k 0.8× 436 0.6× 678 1.1× 318 0.7× 267 0.7× 91 3.9k
P E Keck United States 31 2.5k 0.7× 568 0.8× 1.7k 2.7× 177 0.4× 165 0.4× 51 3.9k
Tom Bschor Germany 35 1.9k 0.6× 1.1k 1.5× 512 0.8× 270 0.6× 134 0.3× 136 3.6k
José Manuel Goikolea Spain 40 4.7k 1.4× 521 0.7× 1.2k 2.0× 95 0.2× 313 0.8× 96 5.4k
Verinder Sharma Canada 32 2.6k 0.8× 414 0.6× 947 1.6× 83 0.2× 457 1.2× 152 4.0k
Ayal Schaffer Canada 36 2.7k 0.8× 836 1.1× 1.6k 2.6× 199 0.5× 233 0.6× 130 4.7k

Countries citing papers authored by Robert W. Baker

Since Specialization
Citations

This map shows the geographic impact of Robert W. Baker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert W. Baker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert W. Baker more than expected).

Fields of papers citing papers by Robert W. Baker

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert W. Baker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert W. Baker. The network helps show where Robert W. Baker may publish in the future.

Co-authorship network of co-authors of Robert W. Baker

This figure shows the co-authorship network connecting the top 25 collaborators of Robert W. Baker. A scholar is included among the top collaborators of Robert W. Baker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert W. Baker. Robert W. Baker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Marder, Stephen R., Eduardo Dunayevich, Jamie Karagianis, et al.. (2010). Case Reports of Postmarketing Adverse Event Experiences With Olanzapine Intramuscular Treatment in Patients With Agitation. The Journal of Clinical Psychiatry. 71(4). 433–441. 39 indexed citations
2.
Perlis, Roy H., Eileen Brown, Robert W. Baker, & Andrew A. Nierenberg. (2006). Clinical Features of Bipolar Depression Versus Major Depressive Disorder in Large Multicenter Trials. American Journal of Psychiatry. 163(2). 225–231. 169 indexed citations
3.
Kennedy, John, Walter Deberdt, Alan P. Siegal, et al.. (2005). Olanzapine does not enhance cognition in non-agitated and non-psychotic patients with mild to moderate Alzheimer's dementia. International Journal of Geriatric Psychiatry. 20(11). 1020–1027. 33 indexed citations
4.
Zhu, Baojin, Sandra L. Tunis, Zhongyun Zhao, et al.. (2005). Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trial. Current Medical Research and Opinion. 21(4). 555–564. 16 indexed citations
5.
Suppes, Trisha, Eileen Brown, Leslie M. Schuh, Robert W. Baker, & Mauricio Tohen. (2005). Rapid versus non-rapid cycling as a predictor of response to olanzapine and divalproex sodium for bipolar mania and maintenance of remission: Post hoc analyses of 47-week data. Journal of Affective Disorders. 89(1-3). 69–77. 33 indexed citations
6.
Houston, John P., et al.. (2005). Initial symptoms of manic relapse in manic or mixed-manic bipolar disorder: Post hoc analysis of patients treated with olanzapine or lithium. Journal of Psychiatric Research. 41(7). 616–621. 14 indexed citations
7.
Kinon, Bruce J., Hong Liu‐Seifert, Jonna Ahl, Saeeduddin Ahmed, & Robert W. Baker. (2004). Longitudinal Effect of Olanzapine on Fasting Serum Lipids: A Randomized, Prospective, 4‐Month Study. Annals of the New York Academy of Sciences. 1032(1). 295–296. 6 indexed citations
8.
Tohen, Mauricio, K. N. Roy Chengappa, Trisha Suppes, et al.. (2004). Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. The British Journal of Psychiatry. 184(4). 337–345. 214 indexed citations
9.
Baker, Robert W., Eileen Brown, Hagop S. Akiskal, et al.. (2004). Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania. The British Journal of Psychiatry. 185(6). 472–478. 40 indexed citations
10.
Baker, Robert W., Mauricio Tohen, Jan Fawcett, et al.. (2003). Acute Dysphoric Mania: Treatment Response to Olanzapine Versus Placebo. Journal of Clinical Psychopharmacology. 23(2). 132–137. 50 indexed citations
11.
Tohen, Mauricio, Robert W. Baker, Lori L. Altshuler, et al.. (2002). Olanzapine Versus Divalproex in the Treatment of Acute Mania. American Journal of Psychiatry. 159(6). 1011–1017. 187 indexed citations
12.
Baker, Robert W., Denái R. Milton, Virginia L. Stauffer, Alan J. Gelenberg, & Mauricio Tohen. (2002). Placebo-controlled trials do not find association of olanzapine with exacerbation of bipolar mania. Journal of Affective Disorders. 73(1-2). 147–153. 12 indexed citations
13.
Tohen, Mauricio, K. N. Roy Chengappa, Trisha Suppes, et al.. (2002). Efficacy of Olanzapine in Combination With Valproate or Lithium in the Treatment of Mania in Patients Partially Nonresponsive to Valproate or Lithium Monotherapy. Archives of General Psychiatry. 59(1). 62–62. 290 indexed citations
14.
Kennedy, John, Frank P. Bymaster, Leslie M. Schuh, et al.. (2001). A current review of olanzapine's safety in the geriatric patient: from pre-clinical pharmacology to clinical data. International Journal of Geriatric Psychiatry. 16(S1). S33–S61. 29 indexed citations
15.
Rush, Craig R. & Robert W. Baker. (2001). Zolpidem and triazolam interact differentially with a delay interval on a digit‐enter‐and‐recall task. Human Psychopharmacology Clinical and Experimental. 16(2). 147–157. 9 indexed citations
16.
Rush, Craig R. & Robert W. Baker. (2001). Behavioral pharmacological similarities between methylphenidate and cocaine in cocaine abusers.. Experimental and Clinical Psychopharmacology. 9(1). 59–73. 70 indexed citations
17.
Rush, Craig R., Robert W. Baker, & James K. Rowlett. (2000). Discriminative-stimulus effects of zolpidem, triazolam, pentobarbital, and caffeine in zolpidem-trained humans.. Experimental and Clinical Psychopharmacology. 8(1). 22–36. 16 indexed citations
18.
Baker, Robert W., Jonathan D. F. Wadsworth, G Brugal, & D. V. Coleman. (1997). An evaluation of ‘rapid review’ as a method of quality control of cervical smears using the AxioHOME microscope. Cytopathology. 8(2). 85–95. 11 indexed citations
19.
Baker, Robert W., G Brugal, & Dulcie V. Coleman. (1996). Assessing Slide Coverage by Cytoscreeners during the Primary Screening of Cervical Smears, Using the AxioHOME Microscope System. Analytical Cellular Pathology. 13(1). 29–37. 1 indexed citations
20.
Zipursky, R.B., Robert W. Baker, & Benjamin Zimmer. (1985). Alprazolam withdrawal delirium unresponsive to diazepam: case report.. PubMed. 46(8). 344–5. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026